CARB-X, working with the Center for Global Development, is advancing NeoTest—an effort designed to accelerate the development and uptake of point-of-care diagnostics for neonatal sepsis. The initiative uses a combined “push and pull” funding structure intended to bridge the gap between innovation and real-world market adoption. The program’s report describes a 10-year, $60 million market-shaping facility with milestone payments to reward development, implementation support to unlock demand, and advanced uptake funding via per-test top-ups. The target product profile focuses on rapid, low-complexity assays that can rule in or out sepsis in newborns up to 59 days old. The approach directly targets antimicrobial resistance-adjacent diagnostics gaps by aligning incentives across developers, health systems, and procurement pathways.